The Cancer Letter: Preclinical Data Show Anti-CD24 Macrophage Checkpoint Inhibitor Promotes Phagocytosis and Shrinks Tumors

New preclinical data for PHST001, an anti-CD24 antibody drug candidate that is designed to block a key macrophage “don’t eat me” signal on cancer cells, were presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer.

Subscribers can read the full article here.  

‍